Results for tag: "Transitional Cell Cancer Drug"

Transitional cell cancer (TCC) is a type of cancer that affects the cells that line the urinary tract and other organs. It is the most common type of bladder cancer and is also known as urothelial cancer. Treatment for TCC typically involves a combination of chemotherapy, radiation therapy, and surgery. Oncology drugs are used to treat cancer and are divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific molecules or pathways in cancer cells, while immunotherapies are designed to stimulate the body's own immune system to fight cancer. The Transitional Cell Cancer Drug market is a subset of the Oncology Drug market. It includes drugs specifically designed to treat TCC, such as chemotherapy drugs, targeted therapies, and immunotherapies. These drugs are used to treat TCC in both early and advanced stages. Some companies in the Transitional Cell Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more